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Opening up opportunities for rare diseases allows exploration of pathogenic mechanisms in
development of rare diseases http://ow.ly/mRj5u
The International Congress on Pulmonary Rare Diseases and Orphan Drugs is a unique European event
which, since 2005, has been held every 2 years in Milan, Italy. The 5th Congress was held in February 2013
(www.pulmonaryrarediseases.com) with the next Congress being held on February 27–28, 2015, in
conjunction with World Rare Diseases Day and during the year of the Universal Exposition 2015, which will
also take place in Milan. Over the years, the Congress has increasingly expanded; it has grown in importance
and has become an important European, as well as international, event. Nowadays, this event is a well-
known and eagerly awaited rendezvous, and has become a valuable asset for the entire international
scientific community in the field of rare (orphan) pulmonary diseases.
The success of this Congress is based on its many profiles, international, translational and clinical, which
gather together scientists from different fields of expertise (from pulmonary hypertension (PH) to
lymphangioleiomyomatosis (LAM)) providing them with a valuable opportunity to encompass a broad
range of insights within the area of respiratory medicine. Although most topics relate to rare pulmonary
diseases, representing the core of the Congress, this year several rare presentations of common respiratory
diseases were covered in the programme, including the management of severe asthma and
hypereosinophilic asthma. Topics for the programme were suggested by an international scientific
committee comprised of outstanding European and US physicians. For example, the 2013 committee
comprised E.H. Bel, V. Cottin, M. Humbert, M. Matucci-Cerinic, J. Moss, G. Simonneau, C. Vancheri, A.
Vonk-Noordegraaf and S. Harari (Congress Chair). The Congress fosters interactions between specialties
and subspecialties, ranging from severe asthma to pulmonary fibrosis, rare presentations of cancer,
connective tissue diseases and PH. Thus, in addition to pulmonologists, other clinical specialists were
involved as speakers and attendees, especially rheumatologists, as well as cardiologists, internal medicine
specialists, immunologists, dermatologists and many others.
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Opening up new prospects and opportunities for rare diseases, by gathering different medical specialties and
involving both researchers and physicians, allows scientists to explore some common pathogenic
mechanisms in the development of rare diseases. Moreover, by integrating different sources of scientific
knowledge, innovative therapeutic approaches may also be tested. The translational approach has recently
been reinforced by moving from basic research to clinical investigation.
The proceedings of the Congresses have been published previously in international journals [1, 2]. Selected
papers from the 2011 Congress have been published previously in the European Respiratory Review (ERR)
[3]. This year, it is a privilege that the proceedings of the 2013 International Congress on Pulmonary Rare
Diseases and Orphan Drugs will be published more extensively in the current issue of the ERR . The
increasing scientific interest for rare pulmonary diseases throughout the entire European medical
community is witnessed by the continuous rise in the number of scientific publications related to these
topics [3], and the growing attention paid to this field by the publications of the European Respiratory
Society (table 1).
The proceedings are developed according to this philosophy, i.e. facing a wide range of problems and
diseases, and always bearing in mind possible common features and links between different conditions.
Thus, the article by WENER and BEL [4] informs us how we can learn to distinguish between ‘‘difficult-to-
control’’ and ‘‘severe refractory’’ asthma, as well as how to practically manage these difficult situations. The
review by GARCIA et al. [5] illustrates the possible role of anti-interleukin-5 compounds in the treatment of
severe eosinophilic asthmatic patients with a history of frequent exacerbations. MONTANI et al. [6]
extensively review the issue of drug-induced pulmonary arterial hypertension (PAH); a story which
resembles that of the Arab Phoenix rising from its ashes. In addition, the authors discuss the most
commonly involved drugs, including aminorex fumarate (which was used in the late 1960s), fenfluramine
(which was used in the 1980s) and the most recently used, benfluorex. Novel therapies and possible future
approaches to PAH are discussed by SEFERIAN and SIMONNEAU [7], experts from one of the most important
European centres dedicated to the research and treatment of pulmonary vascular diseases. DELCROIX [8]
discusses the rationale for the use of PAH-targeted drugs in chronic thromboembolic pulmonary
hypertension, which, until now, was essentially a surgical disease. The highly clinically relevant issue of PH
in interstitial lung diseases (ILD) (ranging from sarcoidosis, idiopathic pulmonary fibrosis (IPF), multiple
cystic lung diseases including LAM, to pulmonary Langerhans’ cell histiocytosis) is reviewed by CAMINATI
et al. [9], including prevalence, mechanisms of disease and possible future therapies. The vast area of ILD is
covered by a number of authors, including COTTIN [10], who offers an exhaustive and modern view on the
significance of connective tissue disease features in patients with pulmonary fibrosis. VANCHERI [11]
discusses the possible links between IPF and lung cancer (a very hot and intriguing topic), and CAPPELLI
et al. [12] discuss the role of immunosuppressive therapy for ILD in the setting of systemic sclerosis.
ANTONIOU et al. [13] review the role of pharmacological treatment in IPF, by looking at future issues and
new interesting ongoing studies, and discuss the critical issue of end-points in clinical trials. Finally, SHIM
et al. [14] explore the experimental and animal data regarding a very particular, relevant and not well-
known problem: the effect of oestrogen in sex-specific lung diseases, especially LAM.
We hope you will enjoy these reviews which provide an interesting adventure through the transversal and
fascinating world of research and clinical approach in medicine.
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